Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

Area of Science:

• Oncology
• Immunotherapy
• Gastrointestinal Cancers

Background:

• Standard adjuvant chemotherapy for stage III colon cancer involves fluoropyrimidine-plus-oxaliplatin regimens.
• The efficacy of adding atezolizumab (anti-PD-L1) to modified FOLFOX6 (mFOLFOX6) in mismatch repair-deficient (dMMR) stage III colon cancer remains under investigation.

Purpose of the Study:

• To evaluate the impact of adjuvant atezolizumab plus mFOLFOX6 on disease-free survival in patients with resected stage III dMMR colon cancer.
• To assess overall survival and the safety profile of this combination therapy.

Main Methods:

• A phase 3, randomized trial comparing atezolizumab plus mFOLFOX6 (12 months total therapy) versus mFOLFOX6 alone (6 months) in resected stage III dMMR colon cancer patients.
• Primary endpoint: disease-free survival. Secondary endpoints: overall survival and adverse events.

Main Results:

• Atezolizumab plus mFOLFOX6 demonstrated a significant improvement in 3-year disease-free survival (86.3% vs. 76.2%) compared to mFOLFOX6 alone.
• The hazard ratio for disease recurrence or death was 0.50 (95% CI, 0.35 to 0.73; P<0.001).
• Grade 3 or 4 adverse events were more frequent in the atezolizumab group (84.1% vs. 71.9%).

Conclusions:

• Adjuvant atezolizumab combined with mFOLFOX6 significantly enhances disease-free survival in stage III dMMR colon cancer.
• The findings support atezolizumab as a valuable addition to standard chemotherapy for this specific patient population.